Syros earnings
WebSyros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of -0.79% and 123.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the... SYRS : 2.51 (-2.15%) VRDN : 25.41 (+1.97%) Web20 hours ago · SYRS: Syros Pharmaceuticals Detailed Earnings Estimate. Get the latest Detailed Estimate from Zacks Investment Research. SYRS: Syros Pharmaceuticals - …
Syros earnings
Did you know?
WebDec 31, 2024 · Syros Pharmaceuticals reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports ... WebApr 10, 2024 · Syros Pharmaceuticals, Inc. (SYRS) delivered earnings and revenue surprises of 38.36% and 21.65%, respectively, for the quarter ended September 2024. Do the …
WebSyros Pharmaceuticals (SYRS) Earnings Date & Reports 641 Followers Portfolio Earnings Data Report Date May 10, 2024 Not Confirmed Period Ending 2024 (Q1) Consensus EPS Forecast -$1.05 Last Year’s EPS -$4 Same Quarter Last Year Analyst Consensus Strong Buy Based on 5 Analysts Ratings Syros Pharmaceuticals (SYRS) Earnings, Revenues Date & … WebApr 12, 2024 · Myelodysplastic Syndrome Epidemiology Insights. The total incident population of MDS in the 7MM was 41,850 in 2024, growing at a CAGR of 0.6% during the study period (2024–2032).
WebSyros Pharmaceuticals’s CEO is Nancy Simonian, appointed in Jul 2012, they has a tenure of 10.8yrs. Their total yearly compensation is US$3.1m, comprised of 19.8% salary and 80.2% bonuses, including company stock and options. They directly owns 0.4% of the company’s shares, worth US$218.3k. The average tenure of the management team and the ... WebApr 15, 2024 · Syros Pharmaceuticals Trading Down 2.5 %. Shares of Syros Pharmaceuticals stock opened at $2.70 on Friday. The firm has a market capitalization of …
WebMar 24, 2024 · Syros Pharmaceuticals (SYRS) (Delayed Data from NSDQ) $2.74 USD -0.07 (-2.49%) Updated Mar 24, 2024 04:00 PM ET After-Market: $2.72 -0.02 (-0.73%) 7:58 PM ET Add to portfolio Zacks Rank: 3-Hold 3...
WebSyros Pharmaceuticals (SYRS) will release its next earnings report on May 11, 2024. In the last quarter Syros Pharmaceuticals reported -$1.225 EPS in relation to -$0.17 expected by … cannot interpret tf.float32 as a data typeWebAug 9, 2024 · Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2024 Results - Earnings Call Transcript Aug. 09, 2024 2:29 PM ET Syros Pharmaceuticals, Inc. (SYRS) SA Transcripts 134.66K Follower... fkusx chartWebSep 23, 2024 · Earnings Estimate Revisions for Syros Pharmaceuticals, Inc. For the fiscal year ending December 2024, this company is expected to earn -$9.51 per share, which is a change of 33% from the... fkv algorithmWebMar 8, 2024 · Syros Pharmaceuticals's Return On Capital Employed Overview - Syros Pharmaceuticals (NASDAQ:SYRS) - Benzinga Español India Italiano Français My Account … fk velocity\u0027sWebApr 15, 2024 · Syros Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $12.93. Syros Pharmaceuticals (NASDAQ:SYRS – Get Rating) last released its quarterly earnings results on Thursday, March 2nd ... cannot interpret torch.float32 as a data typeWebSyros Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. SYRS updated stock price target summary. cannot invoke because it\u0027s nullWebSyros Pharmaceuticals (SYRS) Option Put/Call Volume, Put/Call Open Interest, and Put/Call Ratios to spot long and short option trends. ... Earnings Per Share (trailing 12 months), Net Income, Beta, Annual Dividend, and Dividend Yield. Note: For all markets except U.S. equities, fundamental data is not licensed for downloading. Your .csv file ... cannot invoke - argument type mismatch